XML 28 R47.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies (Details) (USD $)
3 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended
Sep. 30, 2012
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2012
Apr. 30, 2014
830 Winter Street, Waltham, MA
item
Apr. 30, 2012
830 Winter Street, Waltham, MA
sqft
Dec. 31, 2009
830 Winter Street, Waltham, MA
sqft
Dec. 31, 2013
830 Winter Street, Waltham, MA
sqft
Jul. 27, 2007
830 Winter Street, Waltham, MA
sqft
Jun. 30, 2014
Norwood, MA
Jul. 31, 2013
100 River Ridge Drive, Norwood, MA
Apr. 30, 2013
100 River Ridge Drive, Norwood, MA
sqft
Operating leases                        
Area of space leased (in square feet)                 89,000     7,507
Initial lease term period           3 years         5 years 2 months  
Additional area of space leased (in square feet)               19,000        
Construction allowance receivable         $ 1,100,000     $ 746,000        
Number of additional terms for which lease agreement can be extended         2              
Additional term period for which lease agreement can be extended         5 years         5 years 5 years  
Area of property covered under sublease agreement (in square feet)           7,310 14,100          
Additional period for which sublease agreement can be extended             2 years          
Facilities rent expense, net of sublease income   5,400,000 4,800,000 4,800,000                
Minimum rental commitments under the non-cancelable operating lease agreements                        
2015   7,150,000                    
2016   6,924,000                    
2017   6,941,000                    
2018   7,046,000                    
2019   6,235,000                    
Thereafter   43,887,000                    
Total minimum lease payments   78,183,000                    
Total minimum rental income from subleases   (408,000)                    
Total minimum lease payments, net   77,775,000                    
Obligations under capital leases   0                    
Collaborations                        
Potential future success-based milestone and third-party payments cancelled under license agreement with Janssen Biotech 41,000,000                      
Potential milestone payments receivable   162,000,000                    
Amount reimbursable by a third party   $ 1,400,000